Teva’s Cinqair To Join Nucala For Severe Asthma After FDA Approval
This article was originally published in The Pink Sheet Daily
FDA approved the interleukin-5 antagonist reslizumab March 23 for the treatment of severe asthma in patients 18 and older who have an eosinophilic phenotype.
You may also be interested in...
Mepolizumab would be first drug for chronic obstructive pulmonary disorder to use eosinophil count as a biomarker, but FDA’s complete response letter says more clinical data are needed.
AstraZeneca/Daiichi Sankyo's Enhertu is poised to become the new standard of care for second-line HER2-positive breast cancer after handedly beating Roche's Kadcyla on PFS.
Regeneron's Eylea and Roche's Lucentis currently dominate the treatment market for wet-AMD and diabetic eye disease, but biosimilar ranibizumab and new brand launches are on the horizon.